Interestingly, among the fourteen recurrent GBM patients treated with rQNestin34.5v.2 (ClinicalTrials.gov, NCT03152318), the IGF2 expression level was significantly increased in ten patients out of fourteen (71.4%) after rQNestin34.5v.2 treatment (P  = .0020).16 However, the expression level of the IGF1 gene was increased in only four patients (28.6%; P  = .1250; Figure 1B). The gene discussed is IGF1; the disease is glioblastoma.